zanidatamab
zanidatamab: 15 clinical trials tracked.
zanidatamab evidence translation
What we can confirm
15 tracked trials
What it means
What to watch
Prepared research question
What is verified about zanidatamab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Clinical Trials (15)showing 10 most recent
Real-World Utilization, Treatment Patterns, Tolerability, and Effectiveness of Zanidatamab in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma in the United States
Primary endpoint: Average age of participants
AACR Adaptive Biomarker-Driven Organ Preservation Trial In Gastroesophageal Adenocarcinomas (AACR-ADOPT-GEA)
Primary endpoint: Pathological Complete Response (pathCR) Rate (Stage I).
A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer
Primary endpoint: Rate of Complete and Major Pathologic Regression (Cohort 1)
- ZANGEA - Phase II Study of Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
Primary endpoint: Efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in previously untreated HER2 and PD-L1 positive metastatic gastroesophageal adenocarcinoma (GEA)
Widening Treatment Options Among Adult Patients With HER2-overexpressing or Mutant Solid Cancers.
Primary endpoint: Confirmed Objective Response Rate (ORR) by investigator
A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Primary endpoint: Number of participants with pCR
A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)
Primary endpoint: Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR
A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
Primary endpoint: Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)
An Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer
Primary endpoint: Progression Free Survival (PFS) in participants with Immunohistochemistry (IHC) 3+ tumors
Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial
Primary endpoint: Progression-free survival (PFS)